This Year 2017 in Aperplexing World
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
LINKING INFECTIOUS and NARCOLOGY CARE) Evidence-Based for Engagement in HIV Care
COMPENDIUM OF EVIDENCE-BASED INTERVENTIONS AND BEST PRACTICES FOR HIV PREVENTION LINC (LINKING INFECTIOUS AND NARCOLOGY CARE) Evidence-Based for Engagement in HIV Care INTERVENTION DESCRIPTION Goal of Intervention • Improve engagement in HIV care • Improve retention in HIV care • Improve CD4+ cell count • Reduce self-reported hospitalizations Target Population • HIV-positive injecting drug users in treatment Brief Description LINC (Linking Infectious and Narcology Care) is an individual-level, strengths-based case management intervention for HIV-positive persons who inject drugs (PWID). It is adapted from the Antiretroviral Treatment Access Study (ARTAS). LINC involves coordination between the HIV and narcology systems of care to reduce barriers to HIV care and help motivate HIV-positive PWID to engage in care by supporting recognition of one’s strengths to make positive life changes. The initial session is delivered in a narcology hospital (e.g., in-patient addiction treatment setting) and includes provision of CD4 test results to increase engagement in HIV medical care. After discharge, subsequent sessions are conducted in community or clinic locations over six months. LINC aims to build self-efficacy, enable self-management, and increase outcome expectancies regarding engaging in HIV care via education and social support. Theoretical Basis • Social Cognitive Theory (SCT) • Psychological Empowerment Theory (PET) Intervention Duration • Five sessions delivered over six months Intervention Settings • Narcology hospital • Community or clinic locations • Phone Deliverer • Peer case managers (i.e., HIV-infected men and women in recovery from addiction) LRC Chapter – LINC (Linking Infectious and Narcology Care) Last updated March 17, 2020 COMPENDIUM OF EVIDENCE-BASED INTERVENTIONS AND BEST PRACTICES FOR HIV PREVENTION Delivery Methods • Case management • Printed materials • Discussion • Video • Goal setting Structural Components There are no reported structural components reported for this study. -
Summary Analgesics Dec2019
Status as of December 31, 2019 UPDATE STATUS: N = New, A = Advanced, C = Changed, S = Same (No Change), D = Discontinued Update Emerging treatments for acute and chronic pain Development Status, Route, Contact information Status Agent Description / Mechanism of Opioid Function / Target Indication / Other Comments Sponsor / Originator Status Route URL Action (Y/No) 2019 UPDATES / CONTINUING PRODUCTS FROM 2018 Small molecule, inhibition of 1% diacerein TWi Biotechnology / caspase-1, block activation of 1 (AC-203 / caspase-1 inhibitor Inherited Epidermolysis Bullosa Castle Creek Phase 2 No Topical www.twibiotech.com NLRP3 inflamasomes; reduced CCP-020) Pharmaceuticals IL-1beta and IL-18 Small molecule; topical NSAID Frontier 2 AB001 NSAID formulation (nondisclosed active Chronic low back pain Phase 2 No Topical www.frontierbiotech.com/en/products/1.html Biotechnologies ingredient) Small molecule; oral uricosuric / anti-inflammatory agent + febuxostat (xanthine oxidase Gout in patients taking urate- Uricosuric + 3 AC-201 CR inhibitor); inhibition of NLRP3 lowering therapy; Gout; TWi Biotechnology Phase 2 No Oral www.twibiotech.com/rAndD_11 xanthine oxidase inflammasome assembly, reduced Epidermolysis Bullosa Simplex (EBS) production of caspase-1 and cytokine IL-1Beta www.arraybiopharma.com/our-science/our-pipeline AK-1830 Small molecule; tropomyosin Array BioPharma / 4 TrkA Pain, inflammation Phase 1 No Oral www.asahi- A (ARRY-954) receptor kinase A (TrkA) inhibitor Asahi Kasei Pharma kasei.co.jp/asahi/en/news/2016/e160401_2.html www.neurosmedical.com/clinical-research; -
Boletin De Documentación Nº 37, Marzo De 2009
Su elaboración en formato electrónico, iniciada en julio de 2002, ha supuesto importantes ventajas de cara a ampliar y agilizar su difusión entre los profesionales del sector, permitiendo asimismo la localización de documentación relevante por parte de cualquier ciudadano interesado en el campo de las drogodependencias. Como en los números anteriores, en el boletín de marzo se recogen las principales novedades bibliográficas que, sobre los distintos aspectos relacionados con las adicciones, han tenido entrada en el Centro de Documentación e Información de la Delegación del Gobierno para el Plan Nacional sobre Drogas en los tres últimos meses. El contenido del Boletín está estructurado en tres grandes epígrafes: Novedades bibliográficas (clasificadas por su temática y con indicación de su ruta en el caso de que estén disponibles a texto completo en Internet), Legislación y Sumarios de revistas. Esperamos que el Boletín, cuya difusión se realiza a través de listas de distribución de correo electrónico y de su presencia permanente en la página web de la Delegación del Gobierno para el Plan Nacional sobre Drogas, sea de interés y quedamos a la espera de cualquier sugerencia y/o consulta que sobre el mismo queráis formular. Ministerio de Sanidad y Consumo. Delegación del Gobierno para el Plan Nacional sobre Drogas José del Val – E-correo: [email protected] Jefe de Servicio del Centro de Documentación e Información 1 Aspectos Generales ........................................................................ 4 Aspectos Sociales ............................................................................ -
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products. -
Use of the Communication Checklist
Psychiatria Danubina, 2020; Vol. 32, Suppl. 1, pp 88-92 Conference paper © Medicinska naklada - Zagreb, Croatia USE OF THE COMMUNICATION CHECKLIST - SELF REPORT (CC-SR) IN SCHIZOPHRENIA: LANGUAGE IMPAIRMENTS CORRELATE WITH POOR PREMORBID SOCIAL ADJUSTMENT Daria Smirnova1,2, Svetlana Zhukova3, Olga Izmailova4, Ilya Fedotov5, Yurii Osadshiy6, Alexander Shustov7, Anna Spikina8, Dmitriy Ubeikon9, Anna Yashikhina2, Natalia Petrova10, Johanna Badcock1, Vera Morgan1 & Assen Jablensky1 1Centre for Clinical Research in Neuropsychiatry, University of Western Australia, Perth, Australia 2Department of Psychiatry, Narcology, Psychotherapy and Clinical Psychology, Samara State Medical University, Samara, Russia 3Department of Psychiatry, Narcology and Psychology, Ivanovo State Medical Academy, Ivanovo, Russia 4Samara District Clinical Psychiatric Hospital, Samara, Russia 5Department of Psychiatry, Ryazan State Medical University n.a. academician I.P. Pavlov, Ryazan, Russia 6Department of Psychiatry, Narcology and Medical Psychology, Rostov State Medical University, Rostov-on-Don, Russia 7National Medical Research Centre of Psychiatry and Narcology n.a. V.P. Serbsky, Moscow, Russia 8Psychoneurological dispensary ʋ2, Saint Petersburg, Russia 9Department of Psychiatry, Narcology and Psychotherapy with the course of General and Medical psychology, S.I. Georgievsky Medical Academy, V.I. Vernadsky Crimean Federal University, Simferopol, Republic of Crimea, Russia 10Department of Psychiatry and Narcology, Saint Petersburg State University, Saint Petersburg, -
Workbook Psychiatry and Narcology
Kharkiv National Medical University Department of Psychiatry, Narcology and Medical Psychology WORKBOOK MANUAL FOR INDIVIDUAL WORK FOR MEDICAL STUDENTS PSYCHIATRY AND NARCOLOGY (Part 2) Student ___________________________________________________________ Faculty _________________________________________________________ Course _________________ Group _____________________________________ Kharkiv 2019 Затверджено вченою радою ХНМУ Протокол №5 від 23.05.2019 р. Psychiatry (Part 2) : workbook manual for individual work of students / I. Strelnikova, G. Samardacova, К. Zelenska – Kharkiv, 2019. – 103 p. Копіювання для розповсюдження в будь-якому вигляді частин або повністю можливо тільки з дозволу авторів навчального посібника. CLASS 7. NEUROTIC DISORDERS. CLINICAL FORMS. TREATMENT AND REHABILITATION. POSTTRAUMATIC STRESS DISORDER. TREATMENT AND REHABILITATION. Psychogenic diseases are a large and clinically varied group of diseases resulting from an effect of acute or long-term psychic traumas, which manifest themselves by both mental and somatoneurological disorders and, as a rule, are reversible. Psychogenic diseases are caused by a psychic trauma, i.e. some events which affect significant aspects of existence of the human being and result in deep psychological feelings. These may be subjectively significant events, i.e. those which are pathogenic for the majority of people. Besides, the psyche may be traumatized by conventionally pathogenic events, which cause feelings in an individual because of his peculiar hierarchy of values. Unfavorable psychogenic effects on the human being cause stress in him, i.e. a nonspecific reaction at the physiological, psychological and behavioural levels. Stress may exert some positive, mobilizing influence, but may result in disorganization of the organism activity. The stress, which exerts a negative influence and causes various disturbances and even diseases, is termed distress. Classification of neurotic disorders I. -
Young Psychiatrists' Network Meeting “Stigma from the Yps' Perspective: Hopes and Challenges”, September 27-29 2012, Minsk, Belarus
International conference 3rd Young Psychiatrists’ Network Meeting “Stigma From The YPs' perspective: Hopes and Challenges” September 27-29, 2012 Programme and abstract booklet Ministry of Health of the Republic Of Belarus State Educational Establishment “Belarusian Medical Academy of Post-Graduate Education” Supported by Rotary club “Minsk” International conference 3rd Young Psychiatrists’ Network Meeting “Stigma From The YPs' perspective: Hopes and Challenges” September 27-29, 2012 Programme and abstract booklet Ltd “Magic” Minsk 2012 UDC (УДК) 61 LCN (ББК) 56.14 Scientific edition 3rd Young Psychiatrists' Network Meeting “Stigma From The YPs' perspective: Hopes and Challenges”, September 27-29 2012, Minsk, Belarus. International conference: Programme and abstract booklet. – Minsk: Publishing house “Magic“, 2012. - 84 p. ISBN 978 – 985-6473-81-7 Supported by European Federation of Psychiatrists’ Trainees (EFPT) Supported by Belarusian Medical Academy of Post-Graduate Education (BelMAPGE) Supported by Belarusian Psychiatric Association (BPA) Supported by Rotary club “Minsk” Editorial Board: J. Hanson, MD, PhD, Assoc. Prof., Sweden; D. Krupchanka, MD, PhD student, Belarusian Medical Academy of Postgraduate Education, Minsk, Belarus; N. Bezborodovs, MD, Riga Stradins University, Riga Centre of Psychiatry and Addiction Disorders, Latvia; M. Bendix, MD, Dr. Med., Karolinska University Hospital Huddinge, Sweden; S. Jauhar, MD, MBChB, BSc (Hons), MRCPsych, Department of Psychosis Studies, Institute of Psychiatry, United Kingdom; D. Smirnova, MD, PhD, Samara State Medical University, Russian Federation. ISBN 978 – 985-6473-81-7 © State Educational Establishment “Belarusian Medical Academy of Post- Graduate Education” Anyone who keeps learning stays young. The greatest thing in life is to keep your mind young. (c) There is a story of our meetings. -
Bioethical Differences Between Drug Addiction Treatment Professionals Inside and Outside the Russian Federation Mendelevich
Bioethical differences between drug addiction treatment professionals inside and outside the Russian Federation Mendelevich Mendelevich Harm Reduction Journal 2011, 8:15 http://www.harmreductionjournal.com/content/8/1/15 (10 June 2011) Mendelevich Harm Reduction Journal 2011, 8:15 http://www.harmreductionjournal.com/content/8/1/15 RESEARCH Open Access Bioethical differences between drug addiction treatment professionals inside and outside the Russian Federation Vladimir D Mendelevich Abstract This article provides an overview of a sociological study of the views of 338 drug addiction treatment professionals. A comparison is drawn between the bioethical approaches of Russian and foreign experts from 18 countries. It is concluded that the bioethical priorities of Russian and foreign experts differ significantly. Differences involve attitudes toward confidentiality, informed consent, compulsory treatment, opioid agonist therapy, mandatory testing of students for psychoactive substances, the prevention of mental patients from having children, harm reduction programs (needle and syringe exchange), euthanasia, and abortion. It is proposed that the cardinal dissimilarity between models for providing drug treatment in the Russian Federation versus the majority of the countries of the world stems from differing bioethical attitudes among drug addiction treatment experts. Introduction deontological norms [6,10]. Although there have been Russian and international narcology (addiction medi- calls for adherence to the principles of medical ethics, cine) began to develop along divergent paths during the the procedures put into practicecontinuetobeincom- second half of the twentieth century. Indeed, Russian patible with these principles. Drug addicts still have narcology has ceased to be a part of international nar- even fewer patient rights than the mentally ill. -
Exam Questions Year 5 Psychiatry and Narcology General Medicine Faculty BSMU (2019/2020)
Exam questions Year 5 Psychiatry and narcology General medicine faculty BSMU (2019/2020) Part 1 1. Object and task of psychiatry and narcology, their place among other medical disciplines. 2. History of psychiatry: middle ages, 19th century, modern psychiatry. 3. Stigma of mental Illness. Central anti-psychiatry beliefs. 4. Frame of psychiatry: general psychopathology, age psychiatry, organizational psychiatry, judicial, psychopharmacotherapy, addictology (narcology), trans-cultural psychiatry, sexology, suicidology. 5. The methods of investigations in psychiatry. 6. The criteria of mental health. Criteria of normality (Rosenhan and Seligman, 1984). 7. Biases that affect diagnoses: racial/ethnic, confirmation bias, institutionalization, reporting bias, cultural differences. 8. Classification in psychiatry, the most important classification categories. 9. Organic and functional disorders in psychiatry. Concepts of neurosis and psychosis. 10. Epidemiology of mental disorders. Prevalence of major psychiatric conditions. 11. Psychiatry examination. 12. Disturbances of perception: hallucinations, types of hallucinations. Pseudo-hallucinations. Circumstances and disorders associated with hallucinations. 13. Disturbances of perception: illusions, types of illusions. 14. Psycho-sensorial disturbances of perception: derealisation, dismorphophobia, methamorphopsias, and depersonalisation. 15. Disorders of mood (emotions): pathological affect, depression, mania, anhedonia, flattened affect, euphoria, emotional lability, inappropriate affect, phobias. -
NGO Directory
National Foundation for Health Progress and Research Development Centre Culturel d'Hussein-Day Africa 16000 Alger Algeria Phone: (213-21)2 31 655 Fax: (213-21) 23 1644 E-mail: [email protected] Contact: Mostefa KHIATI Title: President Founded in: 1990 ECOSOC : Special consultative status Drug Control Activities and Methods of Intervention: Prevention, education, counselling, research, training Repeated awareness raising campaigns Other Areas: Health, prevention of HIV/AIDS, solidarity, training National Foundation for Medical Research Cultural Centre of El-Biar Room 36 Africa El Biar, Algiers Algeria Phone: (213-2) 502 991 Fax: (213-2) 503 675 E-mail: Contact: Prof. Mustapha ACHOUI Title: President Founded in: 1980 ECOSOC : None Drug Control Activities and Methods of Intervention: Prevention, research and rehabilitation of drug abusers. Training of psychologists in prevention and rehabilitation techniques. Organizing and developing training systems. Target groups contacted with a few monographs. Other Areas: Research on various different medical cases. Page: 1 Movimento Nacional Vida Livre M.N.V.L. Av. Comandante Valodia No. 283, 2. And.P.24. Africa C.P. 3969 Angola, Rep. Of Luanda Phone: (244-2) 443 887 Fax: E-mail: Contact: Dr. Celestino Samuel Miezi Title: National Director, Professor Founded in: 1989 ECOSOC : Drug Control Activities and Methods of Intervention: Prevention, education, treatment, counselling, rehabilitation, training, and criminology To combat drugs and its consequences through specialized psychotherapy and detoxification Other Areas: Health, psychotherapy, ergo therapy Maison Blanche (CERMA) 03 BP 1718 Africa Cotonou Benin Phone: (229) 300850/302816 Fax: (229) 30 04 26 E-mail: Contact: Prof. Rene Gilbert AHYI Title: President Founded in: 1988 ECOSOC : None Drug Control Activities and Methods of Intervention: Prevention, treatment, training and education. -
Perspektive 2023
Perspektive 2023 Neue Medikamente in Entwicklung Inhalt 2 Neue Medikamente in Sicht 6 Neue Wege 8 Neue Chancen für Krebspatienten 10 Entzündungen zum Erliegen bringen 13 Infektionen bekämpfen 14 Gegen Krankheiten unterschiedlichster Art 16 Kindermedikamente und Orphan Drugs 19 Medikamente für Männer und Frauen 20 Die neuen Wirkstoffe 23 Der Beitrag Deutschlands 26 Projekte, die bis 2023 zu einer Zulassung führen können 44 Schwerpunkte der vfa-Mitglieder 46 Kontakt Blick voraus Mehr als zehn Jahre dauert es von der Idee bis zur Zulassung, manch- mal mehr als zwanzig. Erfolge mit neuen Medikamenten kann also nur ernten, wer lange vorher gesät hat. Das haben die forschenden Pharma-Unternehmen des vfa in den späten 2000er- und frühen 2010er-Jahren reichlich getan, so dass nun besonders viele Medika- mente in ihrer Erprobung weit fort geschritten sind. Welche es noch vor Ende 2023 bis zu einer Zulassung oder Zulassungserweiterung schaffen könnten, zeigt diese Veröffentlichung. Sie macht deutlich, dass zahlreiche Patientinnen und Patienten gute Aussichten auf bessere Behandlungsmöglich keiten für ihre Leiden haben. vfa – die forschenden Pharma-Unternehmen Perspektive 2023 Neue Medikamente in Sicht Viele Krankheiten sind in den letzten Jahren besser behandelbar geworden, und Patienten und Ärzte hoffen, dass dieser Strom des Fortschritts nicht abreißt. Die Chancen dafür stehen gut. Denn forschende Pharma-Unternehmen entwickeln derzeit gegen mehr als 145 Krankheiten Medikamente, die bis spätestens Ende 2023 die Zulassung erhalten könnten. Das zeigt eine Erhebung des vfa bei seinen Mitgliedsunter nehmen vom Oktober 2019. Demnach könnten bis Ende 2023 insgesamt 434 Sämtliche Projekte, die in der Erhebung erfasst ihrer Projekte zu einer Zulassung oder Zulassungs- wurden, sind ab S. -
DMM Model of Osteoarthritis
WHY DOES MY JOINT HURT: UNDERSTANDING DISEASE PHENOTYPE AND PAIN RELATIONSHIPS USING MOUSE MODELS OF ARTHRITIS Sanaa Zaki A thesis submitted in fulfilment of requirements for the degree of Doctor of Philosophy Faculty of Medicine (Sydney Medical School) The University of Sydney November 2016 i PREFACE The research embodied in this thesis was conducted at the Raymond Purves Laboratories of Bone and Joint Research, Kolling Institute of Medical Research, University of Sydney at the Royal North Shore Hospital, St Leonards, Australia. Institutional ethics committee approval was sought and obtained prior to the commencement of all animal experiments. The research was partly funded by Arthritis Australia. I certify that the intellectual content of this thesis is the product of my own work, including the design, conduct and analysis of experiments presented in this thesis. Contributions of other researchers and all the assistance received in preparing this thesis and relevant sources have been acknowledged. This thesis has not been submitted for any degree or other purpose. Sanaa Zaki ii ACKNOWLEDGEMENTS My PhD candidature has been a very long journey and I have many colleagues, friends and family that I need to acknowledge for their contribution. Firstly, I am forever indebted to the support and mentorship of my two supervisors, Mark Connor and Chris Little. They graciously bestowed me with the freedom to pave my own path of scientific discovery, while always being there to guide and redirect me when I needed it the most. I am truly indebted to their academic brilliance, scientific rigor and boundless patience. They are truly inspirational researchers that I can only hope to, one day, emulate.